In vitro modeling of glioblastoma initiation using PDGF-AA and p53-null neural progenitors.
GBM
PDGF-AA
genome instability
glioblastoma
model
p53
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
17 08 2020
17 08 2020
Historique:
pubmed:
17
4
2020
medline:
7
4
2021
entrez:
17
4
2020
Statut:
ppublish
Résumé
Imagining ways to prevent or treat glioblastoma (GBM) has been hindered by a lack of understanding of its pathogenesis. Although overexpression of platelet derived growth factor with two A-chains (PDGF-AA) may be an early event, critical details of the core biology of GBM are lacking. For example, existing PDGF-driven models replicate its microscopic appearance, but not its genomic architecture. Here we report a model that overcomes this barrier to authenticity. Using a method developed to establish neural stem cell cultures, we investigated the effects of PDGF-AA on subventricular zone (SVZ) cells, one of the putative cells of origin of GBM. We microdissected SVZ tissue from p53-null and wild-type adult mice, cultured cells in media supplemented with PDGF-AA, and assessed cell viability, proliferation, genome stability, and tumorigenicity. Counterintuitive to its canonical role as a growth factor, we observed abrupt and massive cell death in PDGF-AA: wild-type cells did not survive, whereas a small fraction of null cells evaded apoptosis. Surviving null cells displayed attenuated proliferation accompanied by whole chromosome gains and losses. After approximately 100 days in PDGF-AA, cells suddenly proliferated rapidly, acquired growth factor independence, and became tumorigenic in immune-competent mice. Transformed cells had an oligodendrocyte precursor-like lineage marker profile, were resistant to platelet derived growth factor receptor alpha inhibition, and harbored highly abnormal karyotypes similar to human GBM. This model associates genome instability in neural progenitor cells with chronic exposure to PDGF-AA and is the first to approximate the genomic landscape of human GBM and the first in which the earliest phases of the disease can be studied directly.
Sections du résumé
BACKGROUND
Imagining ways to prevent or treat glioblastoma (GBM) has been hindered by a lack of understanding of its pathogenesis. Although overexpression of platelet derived growth factor with two A-chains (PDGF-AA) may be an early event, critical details of the core biology of GBM are lacking. For example, existing PDGF-driven models replicate its microscopic appearance, but not its genomic architecture. Here we report a model that overcomes this barrier to authenticity.
METHODS
Using a method developed to establish neural stem cell cultures, we investigated the effects of PDGF-AA on subventricular zone (SVZ) cells, one of the putative cells of origin of GBM. We microdissected SVZ tissue from p53-null and wild-type adult mice, cultured cells in media supplemented with PDGF-AA, and assessed cell viability, proliferation, genome stability, and tumorigenicity.
RESULTS
Counterintuitive to its canonical role as a growth factor, we observed abrupt and massive cell death in PDGF-AA: wild-type cells did not survive, whereas a small fraction of null cells evaded apoptosis. Surviving null cells displayed attenuated proliferation accompanied by whole chromosome gains and losses. After approximately 100 days in PDGF-AA, cells suddenly proliferated rapidly, acquired growth factor independence, and became tumorigenic in immune-competent mice. Transformed cells had an oligodendrocyte precursor-like lineage marker profile, were resistant to platelet derived growth factor receptor alpha inhibition, and harbored highly abnormal karyotypes similar to human GBM.
CONCLUSION
This model associates genome instability in neural progenitor cells with chronic exposure to PDGF-AA and is the first to approximate the genomic landscape of human GBM and the first in which the earliest phases of the disease can be studied directly.
Identifiants
pubmed: 32296841
pii: 5820716
doi: 10.1093/neuonc/noaa093
pmc: PMC7594559
doi:
Substances chimiques
Platelet-Derived Growth Factor
0
Trp53 protein, mouse
0
Tumor Suppressor Protein p53
0
platelet-derived growth factor A
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1150-1161Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Cancer Cell. 2019 Apr 15;35(4):692-704.e12
pubmed: 30905762
Nat Cell Biol. 2017 Apr;19(4):282-291
pubmed: 28263958
Cancer Cell. 2014 Aug 11;26(2):288-300
pubmed: 25117714
FEBS Open Bio. 2019 Nov;9(11):1983-1993
pubmed: 31587474
Science. 1992 Mar 27;255(5052):1707-10
pubmed: 1553558
Cancer Res. 1996 Jan 1;56(1):150-3
pubmed: 8548755
Clin Cancer Res. 2009 Oct 1;15(19):6258-66
pubmed: 19789313
Nat Commun. 2018 Aug 6;9(1):3116
pubmed: 30082792
Cell. 2016 Jan 28;164(3):550-63
pubmed: 26824661
Stem Cells. 2009 Aug;27(8):1722-33
pubmed: 19544433
Cold Spring Harb Perspect Biol. 2015 Jan 29;7(5):
pubmed: 25635044
Nat Genet. 2000 May;25(1):55-7
pubmed: 10802656
Acta Neuropathol. 2014 Feb;127(2):203-19
pubmed: 24154962
Glia. 2002 Oct;40(1):25-43
pubmed: 12237841
Histopathology. 1997 Nov;31(5):436-43
pubmed: 9416484
Biology (Basel). 2017 Feb 08;6(1):
pubmed: 28208750
Mol Cell Neurosci. 2010 Jan;43(1):51-9
pubmed: 18761091
Nat Rev Dis Primers. 2019 Sep 19;5(1):64
pubmed: 31537806
Science. 2011 Sep 30;333(6051):1895-8
pubmed: 21960636
Genes Dev. 1998 Dec 1;12(23):3675-85
pubmed: 9851974
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Nature. 1999 Jun 24;399(6738):806-9
pubmed: 10391249
Oncotarget. 2019 Apr 19;10(29):2824-2834
pubmed: 31073373
ASN Neuro. 2013 Mar 08;5(1):e00107
pubmed: 23368675
PLoS One. 2018 Aug 28;13(8):e0202860
pubmed: 30153289
Cell Mol Neurobiol. 2009 Sep;29(6-7):845-58
pubmed: 19288188